Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -100324.78% is 280% below its 5-year average of -26436.00%, near the low end of its 5-year range (-100324.78%–-1750.25%).
66.97% below its 12-month average of -60086.99%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-12-31): -63827.77%.
EBITDA MARGIN
-100324.78%
EBITDA MARGIN AVG TTM
-60086.99%
EBITDA MARGIN AVG 3Y
-45340.95%
EBITDA MARGIN AVG 5Y
-26436.00%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-66.97%
CURRENT VS 3Y AVG
-121.27%
CURRENT VS 5Y AVG
-279.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Creative Medical Technology Holdings, Inc.
Market Cap
$2.37M
EBITDA Margin
-100324.78%
TTM Avg
-60086.99%
3Y Avg
-45340.95%
5Y Avg
-26436.00%
Market Cap
$2.38M
EBITDA Margin
-989.17%
TTM Avg
-572.43%
3Y Avg
-292.90%
5Y Avg
-228.52%
Market Cap
$2.36M
EBITDA Margin
-866.57%
TTM Avg
-750.00%
3Y Avg
-6212.81%
5Y Avg
-4728.90%
Market Cap
$2.47M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.59M
EBITDA Margin
-163.38%
TTM Avg
-126.27%
3Y Avg
-20964.27%
5Y Avg
-20964.27%
Market Cap
$2.64M
EBITDA Margin
-375.69%
TTM Avg
-244.00%
3Y Avg
-166.51%
5Y Avg
-121.60%
Market Cap
$2.05M
EBITDA Margin
-372.74%
TTM Avg
-308.17%
3Y Avg
-306.11%
5Y Avg
-396.88%
Market Cap
$3.09M
EBITDA Margin
-4291.67%
TTM Avg
-3563.06%
3Y Avg
-8274.29%
5Y Avg
-15578.54%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Creative Medical Technology Holdings, Inc. (CELZ) | $2.37M | -100324.78% | -60086.99% | -45340.95% | -26436.00% |
| iTonic Holdings Ltd. (ITOC)vs › | $2.38M | -989.17% | -572.43% | -292.90% | -228.52% |
| GeoVax Labs, Inc. (GOVX)vs › | $2.36M | -866.57% | -750.00% | -6212.81% | -4728.90% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.47M | N/A | N/A | N/A | N/A |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.59M | -163.38% | -126.27% | -20964.27% | -20964.27% |
| iSpecimen Inc. (ISPC)vs › | $2.64M | -375.69% | -244.00% | -166.51% | -121.60% |
| Jaguar Health, Inc. (JAGX)vs › | $2.05M | -372.74% | -308.17% | -306.11% | -396.88% |
| Autonomix Medical, Inc. (AMIX)vs › | $1.92M | N/A | N/A | N/A | N/A |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.09M | -4291.67% | -3563.06% | -8274.29% | -15578.54% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.13M | -22711.52% | -15924.10% | -12940.13% | -12940.13% |
Gross Margin
63.4%
EBITDA Margin
-100324.8%
Operating Margin
-102380.2%
Net Margin
-201355.4%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-12-31 | -63827.77% |
| 2025-03-31 | -54330.03% |
| 2024-12-31 | -62103.17% |
| 2024-06-30 | -19950.44% |
| 2023-12-31 | -58210.60% |
| 2023-09-30 | -25336.07% |
| 2022-12-31 | -33628.58% |
| 2022-09-30 | -1813.46% |
| 2022-03-31 | -7545.65% |
| 2021-12-31 | -2139.66% |
| 2021-09-30 | -8104.15% |
| 2021-06-30 | -4928.21% |
| 2020-12-31 | -1750.25% |
| 2020-09-30 | -293.12% |
| 2020-06-30 | -708.91% |
| 2020-03-31 | -755.97% |
| 2019-12-31 | 7261.30% |
| 2019-09-30 | -466.32% |
| 2019-06-30 | -438.59% |
| 2019-03-31 | -483.10% |
| 2018-12-31 | -546.98% |
| 2018-09-30 | -514.41% |
| 2018-06-30 | -6448.83% |
| 2018-03-31 | -2072.19% |
| 2017-12-31 | 195.19% |
